Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling Pathways in Breast Cancer

Author:

Abouali Gale Dari Mahrokh1,Anbiyaiee Amir2,Moghanibashi Mehdi3,Mohammad Jafari Razieh14,Moramezi Farideh14,Farzaneh Maryam4

Affiliation:

1. Department of Obstetrics and Gynecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2. Department of Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3. Department of Genetics, Faculty of Medicine, Kazerun Branch, Islamic Azad University, Kazerun, Iran

4. Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Abstract: Breast cancer is one of the most common malignancies in women worldwide. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common kinds of invasive breast cancer. Several genetic, epigenetic, and environmental factors could trigger the pathogenesis of breast cancer. Breast cancer treatment generally includes surgery, radiation therapy, chemotherapy, hormonal treatment, targeted therapy, immunotherapeutic, neoadjuvant systemic therapy, and systemic therapy. Although several classical treatment methods are used in cancer therapy, molecular-based strategies can open a new perspective for breast cancer treatment. Previous studies reported that long non-coding RNAs (lncRNAs) play important roles in cancer development and progression. LncRNA TUG1 was found to target several miRNAs and regulate breast cancer cell behavior. TUG1 can induce cell proliferation and invasion of breast cancer cells via downregulation of some miRNAs. Therefore, TUG1 might be a potent biomarker for the treatment of human cancer. In this review, we summarized the functional roles of TUG1 in breast cancer.

Publisher

Bentham Science Publishers Ltd.

Reference51 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3